ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Generics

Cambrex expanding generics R&D in Italy

by Rick Mullin
June 17, 2018 | APPEARED IN VOLUME 96, ISSUE 25

 

Cambrex will expand R&D capabilities for generic active pharmaceutical ingredients (APIs) at its Paullo, Italy, facility. The project will add a 150-m2 laboratory space as well as a research staff expansion. The company currently manufactures more than 70 generic APIs to the FDA’s current Good Manufacturing Practice quality standard. Generics account for approximately 20% of Cambrex’s sales. Earlier this year the company invested $5 million in an expansion of its laboratory facilities in Karlskoga, Sweden, augmenting process development, handling of highly potent substances, and crystallization studies.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment